SkelRegen Replaces its CEO

SkelRegen LLC has a new leader. The West Chester, Pa.-based company has appointed Todd F. La Neve, J.D., as CEO, replacing Stephen R. La Neve, who will continue to serve as co-founder and board director.

Involved since the inception of SkelRegen, Todd La Neve brings more than 20 years’ experience in providing strategic direction and growth for businesses, according to a company news release. A recognized legal expert, Todd La Neve also is a founding member of Circularis LLC, a consulting firm focused on business improvement and optimization in healthcare and other companies. As SkelRegen CEO, he will focus on developing small molecule tissue regeneration technology for clinical trials.

Former SkelRegen CEO Steve La Neve recently was appointed CEO of ETEX Corporation, a Cambridge, Mass.-based developer and manufacturer of bioresorbable bone substitute materials. He has more than 30 years of experience in the healthcare industry.

“Todd’s experience, [which] includes legal expertise and strategic business development, has always been a valued asset to SkelRegen, and we are pleased now to have him officially in the role of CEO,” said Scott D. Boden, M.D., SkelRegen’s co-founder and chief medical and technology officer. “We are also delighted that Steve La Neve will continue to be part of SkelRegen and we look forward to the potential synergies his new position with ETEX will bring to our efforts.”

Boden will continue in his role as co-founder and chief medical, science and technology officer. Boden is a tenured professor of Orthopaedic Surgery at the Emory University School of Medicine in Atlanta, Ga., and serves as the director of the Emory Orthopaedics & Spine Center, vice chairman of Orthopaedics, CMO/CQO of The Emory University Orthopaedics & Spine Hospital, and Emory Healthcare Physician Director of Strategy and Development for Orthopaedics & Spine Programs. He also is the clinical director of the Whitesides Orthopaedic Research Laboratory. John M. Wozney, Ph.D., will remain SkelRegen’s director of scientific affairs and co-owner.

SkelRegen was founded in September 2012. The small molecule musculoskeletal tissue regeneration technology developer was the first to identify multiple small molecules that are osteoinductive and target different aspects of the skeletal tissue formation pathway, the company claims.